Quick-Push immune therapy studied for safety and ease
NCT ID NCT04354129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving Cutaquig® (a medicine that helps fight infections) by a faster manual push method is safe and easy for adults with primary or secondary immunodeficiency. About 36 participants will use the rapid push method at home. The goal is to see if this approach improves safety, comfort, and satisfaction compared to standard methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE DEFICIENCY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for cancer survivors: drug aims to shield against Life-Threatening infections
- Tiny study hunts for hidden genes behind immune failures
- Scientists dig deep into immune system mysteries
- Immune cell therapy shows promise for BK virus in transplant kids
- New transplant approach aims to fix broken immune systems